ASIM ULUSARAC: Open Payments
NPI 1730151671 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,851 in 190 payments from 20 companies in 2025. Trend: 2023 $2,366 · 2024 $2,523 · 2025 $2,851
Food & beverage: $2,851
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $520 |
| Otsuka America Pharmaceutical, Inc. | 31 | $385 |
| Janssen Pharmaceuticals, Inc | 8 | $336 |
| Teva Pharmaceuticals USA, Inc. | 17 | $226 |
| Supernus Pharmaceuticals, Inc. | 25 | $180 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $157 |
| Lundbeck LLC | 14 | $150 |
| Vanda Pharmaceuticals Inc. | 10 | $135 |
| Brainsway USA INC | 1 | $108 |
| Bausch Health US, LLC | 4 | $97 |
Products named: VRAYLAR, REXULTI, SPRAVATO, AUSTEDO XR, Qelbree, CAPLYTA, Deep TMS System, FANAPT.
Industry payments across MO — which companies pay providers there.
